Staging laparotomy and splenectomy in early Hodgkin's disease. No therapeutic benefit
- PMID: 6380286
- DOI: 10.1016/0002-9343(84)90692-2
Staging laparotomy and splenectomy in early Hodgkin's disease. No therapeutic benefit
Abstract
In a prospective randomized study of treatment for early-stage Hodgkin's disease presenting above the diaphragm, 76 patients had staging by laparotomy (Group I) and 28 had staging by closed techniques (Group II). Treatment consisted of involved-field radiotherapy alone (44 patients), involved-field radiotherapy followed by chemotherapy (38 patients), total nodal radiotherapy alone (15 patients), or total nodal radiotherapy followed by chemotherapy (seven patients). On presentation, both groups had similar clinical features and similar treatment distribution. With similar follow-up (87 months), no significant differences in remission or survival were observed between Groups I and II: remission 59 versus 68 percent; survival 74 versus 92 percent; p value 0.27 and 0.09, respectively. Multiple areas of relapse were more frequently observed in Group I (11 of 32 had relapse) as compared with Group II (none of nine had relapse, p less than 0.082). In Group I, relapse in the abdomen was observed as an isolated event or as part of disseminated relapse in 12 percent of patients compared with 3 percent (one patient) in Group II with abdominal relapse alone. Seven patients in Group I and two patients in Group II died with Hodgkin's disease. Six other patients in Group I died with complete remission of non-Hodgkin's lymphoma (one patient), leukoencephalopathy (one patient), sepsis during chemotherapy (two patients), myocardial infarction (one patient), and cerebrovascular accident (one patient). Three other patients in this group had other secondary malignancies successfully controlled (histiocytic lymphoma, squamous cell carcinoma of the cervix, and malignant schwannoma). No second primary lesions or death with complete remission were observed in Group II. Staging laparotomy with splenectomy in early-stage Hodgkin's disease did not improve the duration of remission or survival or decrease the number of abdominal relapses compared with closed staging.
Similar articles
-
Mantle irradiation alone for pathologic stage I and II Hodgkin's disease: long-term follow-up and patterns of failure.Int J Radiat Oncol Biol Phys. 2001 Jul 15;50(4):971-7. doi: 10.1016/s0360-3016(01)01525-5. Int J Radiat Oncol Biol Phys. 2001. PMID: 11429225
-
Subdiaphragmatic Hodgkin's disease: laparotomy and treatment results in 49 patients.J Clin Oncol. 1987 Jul;5(7):1050-5. doi: 10.1200/JCO.1987.5.7.1050. J Clin Oncol. 1987. PMID: 3598609
-
Hodgkin's disease stages IA and IIA. A long-term follow-up study on the gains achieved by modern therapy.Cancer. 1985 Oct 15;56(8):1905-12. doi: 10.1002/1097-0142(19851015)56:8<1905::aid-cncr2820560802>3.0.co;2-u. Cancer. 1985. PMID: 4027927
-
[Questions and aspects of radiotherapy of adult patients with localized supradiaphragmatic stage (CS I/II) Hodgkin's disease. 1. Questions and aspects on indications for primary and adjuvant radiotherapy].Strahlenther Onkol. 1993 Aug;169(8):449-58. Strahlenther Onkol. 1993. PMID: 8356505 Review. German.
-
The use of combination chemotherapy in the treatment of early stage Hodgkin's disease.Important Adv Oncol. 1992:155-65. Important Adv Oncol. 1992. PMID: 1582671 Review. No abstract available.
Cited by
-
Dermatomyositis as presenting symptom of Hodgkin's disease.Ann Hematol. 1991 Aug;63(2):116-8. doi: 10.1007/BF01707284. Ann Hematol. 1991. PMID: 1912031 Review.
-
Current role of gallium scanning in the management of lymphoma.Eur J Nucl Med. 1990;16(8-10):755-71. doi: 10.1007/BF00998184. Eur J Nucl Med. 1990. PMID: 2200680 Review.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical